Skip to main content
MUSTANG BIO, INC. logo

MUSTANG BIO, INC. — Investor Relations & Filings

Ticker · MBIO ISIN · US62818Q1040 LEI · 5493004W0VC1DPECQ779 US Manufacturing
Open in API
Filings indexed 399 across all filing types
Latest filing 2023-07-31 Regulatory Filings
Country US United States of America
Listing US MBIO

About MUSTANG BIO, INC.

https://www.mustangbio.com/

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies. The company's primary focus is on translating medical breakthroughs into potential cures for difficult-to-treat cancers and rare genetic diseases. Its pipeline is centered on Chimeric Antigen Receptor (CAR) T-cell therapies, a form of immunotherapy. Mustang Bio's strategy involves in-licensing promising technologies from academic institutions and advancing them through clinical trials, supported by its in-house manufacturing capabilities to ensure the production and delivery of these advanced treatments.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content focuses on the entry into a material definitive agreement, specifically the second amendment to an Asset Purchase Agreement and related agreements. It details the terms of the transaction, amendments, and related contractual arrangements. There is no indication that this is a full annual or quarterly report, earnings release, or other financial statement. Instead, it is a regulatory filing announcing a material event (a transaction amendment and closing). Form 8-K filings are generally classified under Regulatory Filings (RNS) unless they fit other specific categories, which this does not. Therefore, the appropriate classification is Regulatory Filings (RNS).
2023-07-31 English
8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. The content focuses on the entry into a material definitive agreement, specifically the Third Amendment to a Sublease agreement, detailing changes in leased premises and rent terms. There are no financial statements or earnings data presented, nor is this an annual or quarterly report. The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing a material contract amendment. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2023-07-20 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the termination of a material definitive agreement related to licensing technology, which is a significant corporate event but not a financial report or earnings release. The document is relatively short (4170 characters) and focuses on a specific event rather than financial results or management discussion. Therefore, it fits the category of a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2023-07-11 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-07-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-07-07 English
OWNERSHIP DOCUMENT
Director's Dealing
2023-07-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.